India

AI Citation Summary

• Country: India
• Product line: Medical devices
• Regulator / source: Regulatory Maturity: Moderate. Significant regulatory progress has been made in recent years (the Medical Device Rules 2017 represented a landmark reform), but implementation remains unstable — approval timelines are unpredictable, significant variation exists at the state level, and CDSCO (Central Drugs Standard Control Organisation) technical review capacity is still developing.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Regulatory Maturity: Moderate. Significant regulatory progress has been made in recent years (the Medical Device Rules 2017 represented a landmark reform), but implementation remains unstable — approval timelines are unpredictable, significant variation exists at the state level, and CDSCO (Central Drugs Standard Control Organisation) technical review capacity is still developing.
• Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
• Local requirement: India medical-device entry should be separated into MDR 2017 classification, CDSCO / state licensing jurisdiction, Indian Authorized Agent / importer control, SUGAM submission, Form MD-15 import licence, BIS / Indian standard exposure, local testing, clinical investigation triggers, price-control risk, public procurement, private hospital adoption, service coverage, and state-level distribution. For foreign manufacturers, the commercial bottleneck is often not only registration; it is choosing the right authorised agent, preserving licence control, avoiding price-controlled categories when possible, and proving service reliability to private hospital chains.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Market Overview

• Population: Approximately 1.44 billion (2024, world's largest); enormous potential patient base
• Healthcare System: Severely underfunded public healthcare infrastructure; private hospitals account for approximately 80% of healthcare delivery. Universal health insurance (PM-JAY / Ayushman Bharat) covers approximately 500 million low-income individuals, but actual coverage quality is limited; approximately 60% of healthcare expenditure is out-of-pocket.
• Market Characteristics: India is a large, fast-growing, price-sensitive medical-device market with high import dependence in premium equipment, implants, advanced diagnostics, and high-end consumables. Domestic manufacturers such as Skanray, BPL Medical, Trivitron, Meril, Transasia, Poly Medicure, and others are increasingly competitive in mid-market equipment, consumables, IVD, and local tenders. High-end private hospitals are still the main first channel for imported premium devices, while government procurement is shaped by Make in India, public procurement preference, and price controls.
• Regulatory Maturity: Moderate. Significant regulatory progress has been made in recent years (the Medical Device Rules 2017 represented a landmark reform), but implementation remains unstable — approval timelines are unpredictable, significant variation exists at the state level, and CDSCO (Central Drugs Standard Control Organisation) technical review capacity is still developing.

Market-Entry Logic

India medical-device entry should be separated into MDR 2017 classification, CDSCO / state licensing jurisdiction, Indian Authorized Agent / importer control, SUGAM submission, Form MD-15 import licence, BIS / Indian standard exposure, local testing, clinical investigation triggers, price-control risk, public procurement, private hospital adoption, service coverage, and state-level distribution. For foreign manufacturers, the commercial bottleneck is often not only registration; it is choosing the right authorised agent, preserving licence control, avoiding price-controlled categories when possible, and proving service reliability to private hospital chains.

Entry layer	Key question	Practical view
Classification and pathway	Class A, B, C, D, IVD, notified category, or custom / investigational device?	Classification determines whether state authorities or CDSCO headquarters handle review and whether clinical evidence, testing, or TEC review becomes a critical path
Local responsible structure	Who is the Indian Authorized Agent, importer, licence holder, and PMS executor?	Form MD-15 is held by the Indian agent/importer; contracts must protect dossier access, agent transition, adverse-event reporting, and inventory after termination
Technical evidence	Can CE / FDA files, ISO 13485, test reports, clinical evaluation, and risk files map to MDR 2017?	Overseas dossiers are useful, but local classification, Indian standards, BIS/NABL testing, labelling, and notarisation/apostille requirements must be checked item by item
Commercial access	Is the product for private hospital chains, government tenders, diagnostics networks, home care, or retail?	Premium imported devices usually start in Apollo, Fortis, Max, Manipal, Narayana, and specialist centers; tenders require price and local-content strategy
Pricing and localisation	Is the product exposed to NPPA price caps, public procurement preference, customs duty, GST, or PLI-driven domestic competition?	High-value consumables and mature equipment need landed-cost and price-control scenarios before registration investment

Main Players and Channel Map

Type	Representative players	Market meaning
Regulator / review	CDSCO, DCGI, state licensing authorities, BIS, NABL, Indian Pharmacopoeia Commission	Determine classification, import licence, testing, standards, local inspection, PMS, and distribution enforcement
Pricing / procurement	NPPA, Department of Pharmaceuticals, HLL Lifecare, CMSS, GeM, state health departments, PM-JAY	Determine price caps, public tender access, package rates, local-content preferences, and margin room
Domestic medtech	Skanray, BPL Medical, Trivitron, Meril Life Sciences, Transasia, Poly Medicure, Sahajanand Medical Technologies, Molbio Diagnostics	Compete in monitoring, imaging, IVD, consumables, stents, orthopaedics, diagnostics, and public procurement
Multinational device companies	Siemens Healthineers, GE HealthCare, Philips, Medtronic, Johnson & Johnson MedTech, Abbott, BD, Roche Diagnostics, Danaher / Beckman Coulter	Strong in imaging, intervention, diagnostics, implants, surgical and hospital systems, but exposed to price and localisation pressure
Hospital / diagnostic channels	Apollo, Fortis, Max, Manipal, Narayana Health, Aster, Dr. Lal PathLabs, Metropolis, Thyrocare and regional chains	Drive premium adoption, reference sites, testing volume, service expectations, and metro-to-tier-city expansion
Distribution and service	National importers, regional distributors, service engineers, stockists, installation / maintenance providers	Execute customs, tenders, installation, training, spare parts, uptime commitments, and receivables

Development Trends

1. Regulatory coverage is broadening toward full device regulation: The practical effect of MDR 2017 and later notifications is that legacy "unregulated" device categories now need systematic classification, licensing, and PMS planning.
2. Local manufacturing is moving from policy slogan to procurement lever: PLI schemes, medical-device parks, public procurement preference, and domestic champions make local assembly, contract manufacturing, or India-specific SKUs more relevant.
3. Price control remains category-specific but commercially material: Stents, implants, and other essential devices show how NPPA intervention can compress margins rapidly.
4. Private hospital chains remain the best entry channel for premium imports: They care about clinical differentiation, service uptime, training, and financing more than lowest price alone.
5. Diagnostics, home care, digital health, and low-cost equipment are expanding: Growth outside metro hospitals increases the importance of regional distributors, after-sales support, and affordable configurations.

Regulatory Authority

• Competent Authority: CDSCO (Central Drugs Standard Control Organisation), under the Ministry of Health and Family Welfare (MoHFW)
• Official Portals: https://cdsco.gov.in; Online application system: https://sugam.egateway.gov.in
• Key Regulations:
  • Medical Device Rules 2017 (MDR 2017, effective June 2017; replaced Schedule M III of the Drugs and Cosmetics Act)
  • Drugs and Cosmetics Act 1940 (parent legislation for MDR 2017)
  • Medical Device (Amendment) Rules 2020 and 2022 (multiple subsequent amendments)
  • In Vitro Diagnostics Device Rules 2017 (separate rules for IVDs)
  • 2022 expansion of the medical device definition bringing additional products under regulatory scope

Device Classification System

Local Classification	Risk Level	EU/FDA Equivalent	Description
Class A	Lowest risk	EU Class I / FDA Class I	Declaration/registration filing system; handled by State Licensing Authority (SLA); relatively straightforward
Class B	Low-moderate risk	EU Class IIa / FDA Class II	Registration license system; approved by State Licensing Authority
Class C	Moderate-high risk	EU Class IIb / FDA Class III	Registration license system; CDSCO headquarters review; clinical evidence typically required
Class D	Highest risk	EU Class III / FDA PMA	Registration license system; most rigorous CDSCO headquarters review; clinical investigation data required

Note: MDR 2017 has progressively expanded the scope of "regulated devices" — only 23 categories were included in 2017; since 2022, virtually all medical devices require registration. Refer to CDSCO's Medical Device Classification Guidelines for classification determinations.

Registration Pathways

During the limited-time free period, sign in or register to view the complete medical device country report.